C-CZZNAI-enabled drug discovery, core aging mechanisms, small molecules/biologics/cell therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop heteroaryl amide inhibitors of CD38 as therapeutics related to aging biology.
Small-molecule heteroaryl amide compounds targeting CD38.
Patent application US20230382901A1 published for heteroaryl amide inhibitors of CD38; later listed with granted version US12509451B2 in the supplied patent record.
Regenerate cells and support organ regrowth as part of Juvenescence's longevity-focused therapeutic strategy.
Cell regeneration / regenerative medicine approach.
Presented by Dr. Greg Bailey as one of Juvenescence's areas of focus at Master Investor 2022.
Address aging of the immune system as part of Juvenescence's longevity therapeutic focus.
Undisclosed intervention targeting immune-system aging.
Presented by Dr. Greg Bailey as one of Juvenescence's areas of focus at Master Investor 2022.
Address aging of the immune system as part of Juvenescence's longevity drug-development strategy.
Undisclosed therapeutic research program focused on immune-system aging.
Juvenescence presented addressing aging of the immune system as an area of focus in a Master Investor 2022 company overview.
Evaluate tolerability, safety, and ketone-elevating effects of a novel exogenous ketogenic ester in healthy adults.
28-day randomized, double-blind, placebo-controlled parallel trial of a beverage containing 12.5 g then 25 g/day BH-BD versus placebo.
Published randomized controlled safety and tolerability trial in healthy adults, NCT04707989.
BH-BD increased blood ketone concentrations 1 hour after consumption and showed no clinically meaningful changes in tolerability or safety measures compared with placebo up to 25 g/day.
Evaluate tolerability, safety, and ketone-elevating effects of the exogenous ketogenic ester bis-hexanoyl-(R)-1,3-butanediol in healthy adults.
28-day randomized, double-blind, placebo-controlled parallel trial in healthy adults, using daily beverage consumption of 12.5 g then 25 g BH-BD.
Randomized controlled trial NCT04707989 reported 28-day tolerability and safety results.
BH-BD increased blood ketone concentrations 1 hour post-consumption, with no clinically meaningful safety changes and no tolerability differences versus placebo reported.
Generate hypoimmunogenic cells with high clinical and commercial value.
Cell engineering strategies to reduce immunogenicity.
Publication listed on engineering strategies for generating hypoimmunogenic cells.
Discover and develop medicines targeting core aging mechanisms to extend healthy lifespan and prevent age-related diseases.
AI and data science tools combined with adaptive clinical trial designs across small molecules, biologics, and cell therapies.
Company site describes Juvenescence as a clinical-stage drug development company using AI, data science, and adaptive clinical trial designs for medicines targeting aging pathways.
Support discovery and development of medicines that target core pathways of aging and age-related disease.
Use of AI and data science tools alongside adaptive clinical trial designs across small molecules, biologics, and cell therapies.
Juvenescence describes its medicines and development approach as using AI, data science tools, and adaptive clinical trial designs.
Develop small-molecule drugs for diseases of aging.
Small-molecule drug discovery/development through Antoxerene collaboration.
Antoxerene closed a $10 million deal with Juvenescence to develop small-molecule drugs for diseases of aging.
Develop small-molecule drugs for diseases of aging.
Small-molecule drug discovery and development collaboration with Antoxerene/Juvenescence.
Antoxerene closed a $10 million deal with Juvenescence to develop small-molecule drugs for diseases of aging.
Evaluate tolerability, safety, and ketone-raising effects of a novel exogenous ketone diester in healthy adults.
28-day randomized, double-blind, placebo-controlled parallel trial in healthy adults, using daily BH-BD beverage dosing of 12.5 g then 25 g.
A randomized controlled trial reported tolerability, safety, and blood ketone outcomes for up to 25 g/day BH-BD.
BH-BD significantly increased blood ketone concentrations 1 hour after consumption, with no clinically meaningful safety changes and no tolerability differences versus placebo reported in the supplied abstract.
Develop a core medicine targeting aging biology.
Undisclosed compound/program; site evidence mentions data presentations by a Buck Institute collaborator and Juvenescence personnel.
Eric Verdin presented data on Juvenescence's compound; Rosalba presented data from Juvenescence's core medicine.